Randall joins Avantis Medical from TranS1, where he was most recently CEO.
Prior to TranS1, he held CEO positions with Innovasive Devices and Target Therapeutics.
Avantis Medical Systems markets the Third Eye Retroscope, an FDA-cleared, disposable, catheter-based camera indicated for use with a standard colonoscope to provide an additional view of the colon for diagnostic purposes.
Deployed through the instrument channel of a standard colonoscope, the Third Eye provides the physician with a backward view to complement the colonoscope’s forward view of the lining of the colon.
Avantis vice chairman Matthew Jenusaitis said the Avantis Third Eye Retroscope technology has been clinically demonstrated to improve the detection of pre-cancerous adenomas during colonoscopy.
"The addition of Rick as the chairman and CEO provides one of the last key ingredients to effectively commercializing the technology and providing its benefits to the 15 million patients undergoing this important procedure in the US each year," Jenusaitis said.
Randall said the published clinical outcomes, generated by several studies involving more than 1,000 patients examined with the Third Eye Retroscope, will enable Avantis to redefine the role of colonoscopy in the diagnosis and management of colorectal cancer.
